Previous close | 8.78 |
Open | 8.86 |
Bid | 8.63 x 100 |
Ask | 8.88 x 100 |
Day's range | 8.65 - 8.89 |
52-week range | 3.92 - 11.85 |
Volume | |
Avg. volume | 59,820 |
Market cap | 144.936M |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | 20.02 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conf
NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company’s historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 m
NEWARK, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its fourth quarter results for the period ended December 31, 2023 before the market opens on Thursday, February 15, 2024. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 15, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our inve